Design Therapeutics Inc. (DSGN)
$14.42
$0.32
(2.27%)
As on 08-May-2026 10:37EDT
Market cap
$909 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
62,456,974
5 Years Aggregate
CFO
$-148.06 Mln
EBITDA
$-191.31 Mln
Net Profit
$-171.34 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
| 53.7 | 18.0 | 44.9 | 333.0 | 23.9 | -12.5 | -- |
|
BSE Sensex
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Design Therapeutics (DSGN)
| 52.0 | 131.2 | -74.2 | -52.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Design Therapeutics (DSGN)
|
14.4 | 908.8 | 0.0 | -69.7 | -- | -33.4 | -- | 3.8 |
| 74.1 | 11,082.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 49.5 | 18.5 | |
| 47.8 | 12,241.0 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.2 | |
| 92.7 | 12,229.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.8 | 7,860.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 25.9 | 156.7 | |
| 297.5 | 8,519.4 | 389.1 | 204.8 | 41.5 | 18.9 | 38.7 | 6.6 | |
| 513.5 | 12,443.8 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.8 | |
| 425.4 | 12,189.0 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.9 | 19.9 | |
| 107.0 | 8,234.3 | 0.0 | -425.4 | -- | -36.7 | -- | 6.5 | |
| 338.9 | 9,422.8 | 0.0 | -303.3 | -- | -45.8 | -- | 10.7 |
Shareholding Pattern
View DetailsAbout Design Therapeutics (DSGN)
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC... platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California. Address: 6005 Hidden Valley Road, Carlsbad, CA, United States, 92011 Read more
-
Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Mr. Pratik Shah Ph.D.
-
Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Mr. Pratik Shah Ph.D.
-
Headquarters
Carlsbad, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Design Therapeutics (DSGN)
What is the current share price of Design Therapeutics Inc (DSGN) Today?
The share price of Design Therapeutics Inc (DSGN) is $14.42 (NASDAQ) as of 08-May-2026 10:37 EDT. Design Therapeutics Inc (DSGN) has given a return of 23.91% in the last 3 years.
What is the current PB & PE ratio of Design Therapeutics Inc (DSGN)?
Since, TTM earnings of Design Therapeutics Inc (DSGN) is negative, P/E ratio is not available.
The P/B ratio of Design Therapeutics Inc (DSGN) is 3.77 times as on 07-May-2026, a 15 discount to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-7.66
|
2.52
|
|
2024
|
-7.09
|
1.45
|
|
2023
|
-2.22
|
0.53
|
|
2022
|
-9.80
|
1.76
|
|
2021
|
-27.72
|
2.58
|
What is the 52 Week High and Low of Design Therapeutics Inc (DSGN)?
The 52-week high and low of Design Therapeutics Inc (DSGN) are Rs 17.25 and Rs 3.11 as of 08-May-2026.
What is the market cap of Design Therapeutics Inc (DSGN)?
Design Therapeutics Inc (DSGN) has a market capitalisation of $ 909 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Design Therapeutics Inc (DSGN)?
Before investing in Design Therapeutics Inc (DSGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.